The major advantage of using multiple bioinformatics platforms that utilize clinical samples to analyze BDP1 in ovarian cancer is that each platform employs various algorithms to determine statistical significance and confirm results using multiple analyses. Here, BDP1 is linked to ovarian carcinoma.